In conclusion, paclitaxel liposome based chemotherapy combined with PD-1/PD-L1 inhibitor showed effectiveness in patients with advanced NSCLC, including both squamous cell carcinoma and adenocarcinoma, with acceptable safety profile. This evidence concerns the gene CD274 and non-small cell lung carcinoma.